Intensity Therapeutics, Inc. (INTS) income statement

INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30

$3.10−0.18 (-5.49%)

Close on Nov 12, 2026Market cap $10.12MP/E –Yield –

Intensity Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Research & Development	6.79	10	4.79	5.13
General & Administrative	5.19	6.09	3.53	2.42
Operating Expenses	12	17	8.32	7.55
Operating Income	-12	-17	-8.32	-7.55
Interest Expense	–	0	0.31	0.08
Interest & Investment Income	0.18	0.31	0.32	0.00
Other Non-Operating Income	0.19	0.00	–	–
Income Tax Expense	0	0	0	0
Net Income	-12	-16	-11	-7.58
Preferred Dividends	–	0	1.32	0
EPS (Basic)(per share)	-8.56	-29.24	-34.50	-55.50
EPS (Diluted)(per share)	-8.56	-29.24	-34.50	-55.50
Shares Outstanding (Basic, Weighted)(shares)	1.36	0.56	0.34	0.14
Shares Outstanding (Diluted, Weighted)(shares)	1.36	0.56	0.34	0.14

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -156.9%

Financial strength

Current ratio: 3.68
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 329.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.32
Dividend yield: –

See a number that looks wrong?